Jiangsu Aosaikang Pharmaceutical
Privately held: no public share price
Assets
(2 total)
2Total Assets
0Approved
2Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | METSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 3 | EGFR · EGFR T790M (resistant mutant, selective over wild-type EGFR)Small molecule | Non-Small Cell Lung Cancer |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
2030 (1)
December 2030 (1)
ASKC202 + LimertinibPhase 3EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), MET Positive
Est. primary completion 2030-12-30 · NCT07897188 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.